个人简介
教育经历
09/01/1990 - 07/31/1993 河南医科大学，肿瘤药理，硕士
09/01/1993 - 07/31/1996 中国科学院上海药物研究所，肿瘤药理，博士
09/01/1996 - 07/31/1998 中国科学院上海细胞生物学研究所，细胞生物学，博士后
03/01/2000 - 06/30/2002 University of Pittsburgh, USA, 药理学，博士后
工作经历
08/01/1985 - 07/31/1990 浙江省衢州卫生学校，教员
08/01/1998 - 02/28/2000 中国科学院上海药物研究所，肿瘤药理，副研究员
07/01/2002 - 12/01/2002 中国科学院上海药物研究所，肿瘤药理，副研究员
01/01/2003 - 至今 中国科学院上海药物研究所，肿瘤药理，研究员
近期论文
查看导师新发文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
1. Jie Zhao, Haitian Quan, Chengying Xie, Liguang Lou*. NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. Pharma Res Per, 2 (2), 2014, e00043.
2. Liping Sun, Haitian Quan, Chengying Xie, Lei Wang, Youhong Hu, Liguang Lou*. Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition. PLOS ONE 2014; e90627.
3. Jie Zhao, Haitian Quan, Yongping Xu, Xiangqian Kong, Lu Jin, Liguang Lou*. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes imatinib- and sunitinib- resistance of certain KIT mutants. Cancer Science 2014; 105:117-25.
4. Weiping Liu, Qingsong Ye, Jing Jiang, Liguang Lou*, Yongping Xu, Chengying Xie, Mingjin Xie. Cis-[Pt(II)(1R,2R-DACH)(3-Acetoxy- 1,1- cyclobutanedicarboxylato)]：a water-soluble,oxalate-free and stable analogue of oxaliplatin: synthesis, characterization and biological Valuations. ChemMedChem, 2013; 8(9):1465-7
5. Quanren Wang, Haitian Quan, Jie Zhao, Chengying Xie, Lei Wang, Liguang Lou*. RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Letters 2013; 340:43-50
6. Weiping Liu, Xizhu Chen, Qingsong Ye, Shuqian Hou, Liguang Lou* and Chengying Xie. 3-Hydroxycarboplatin, a simple carboplatin derivative endowed withan improved toxicological profile. Platinum Metals Rev 2012; 56: 257–265.
7. Lei Wang, Yongping Xu, Li Fu, Yuanchao Li, Liguang Lou*. (5R)-5- hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition. Cancer Letters, 2012:324:75-82
8. Qiong Wu, Haitian Quan, Yongping Xu, Yun Li, Youhong Hu, Liguang Lou*. p38 MAPK is required for the antitumor activity of the vascular disrupting agent DMXAA. J Pharmacol Exp Ther 2012; 341:709-17.
9. Cheng-Ying Xie, Yong-Ping Xu, Wei Jin, Li-Guang Lou*. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small cell lung cancer. Anti-Cancer Drugs 2012; 23:698-705.
10. Cheng-Ying Xie, Yong-Ping Xu, Hong-Bing Zhao, Li-Guang Lou*. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists. Exp Hematol 2012; 40: 386-92
11. Hongbing Zhao, Haitian Quan, Chengying Xie, Yongping Xu, Fuchun Xie, Youhong Hu, Liguang Lou*. YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance. Cancer Letters 2012; 314: 54-62.
12. Weiping Liu, Xizhu Chen, Qingsong Ye, Yongping Xu, Chengying Xie, Mingjin Xie, Qiaowen Chang, and Liguang Lou*. A Novel Water-Soluble Heptaplatin Analogue with Improved Antitumor Activity and Reduced Toxicity. Inorganic Chemistry 2011; 50:5324-5326
13. Fuchun Xie, Hongbing Zhao, Dewen Li, Hong Chen, Haitian Quan, Xiaojing Shi, Liguang Lou,* and Youhong Hu*. Synthesis and Biological Evaluation of 2, 4, 5-substituted Pyrimidines as a New Class of Tubulin Polymerization Inhibitors. J Med Chem 2011; 54:3200-3205.
14. Tian S, Quan H, Xie C, Guo H, Lu F, Xu Y, Li J*, Lou L*. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011; 102:1374-1380.
15. Luo H, Quan HT, Xie C, Xu Y, Fu L, Lou L*. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia 2010; 24: 1807-9.
16. Xie F, Zhao H, Zhao L, Lou L*, Hu Y*. Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity. Bioorg Med Chem Lett 2009; 19: 275-8.
17. Quan H, Liu H, Li C, Lou L*. 1,4-Diamino-2,3-dicyano-1,4-bis(methylthio) butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase. J Pharmacol Exp Ther. 2009 ; 330:326-33.
学术兼职
《中国药理学通报》，《肿瘤防治与研究》，《新药与临床杂志》编委
中国抗癌协会抗癌药物委员会委员
中国药理学会肿瘤药理委员会委员
上海市药理学会理事
京公网安备 11010802027423号